Literature DB >> 17261764

HER2/neu expression in relation to clinicopathologic features of breast cancer patients.

Adele Traina1, Biagio Agostara, Lorenzo Marasà, Maurizio Calabrò, Maurizio Zarcone, Giuseppe Carruba.   

Abstract

We have evaluated HER2/neu expression in 1,355 breast cancer patients recruited at the Breast Cancer Registry in Palermo between January 1999 and December 2004. In this retrospective study, HER2/neu expression was related to clinicopathologic features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors. Statistical analysis on all 1,355 patients showed a significant correlation between HER2/neu and nodal status (P < 0.001), and a significant association between HER2/neu overexpression and estrogen and progesterone receptors status (P < 0.001). In 194 patients without metastasis, with an average follow-up > or =5 years, only HER2/neu 3+ and histopathologic grading G3 were significantly associated with overall survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17261764     DOI: 10.1196/annals.1386.029

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

2.  The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.

Authors:  Linbo Wang; Zhinong Jiang; Meihua Sui; Jianguo Shen; Chaoyang Xu; Weimin Fan
Journal:  BMC Cancer       Date:  2009-07-11       Impact factor: 4.430

3.  Significance of Her-2/neu protein over expression in Indian breast cancer patients.

Authors:  Vikash Kumar; Mallika Tewari; Usha Singh; H S Shukla
Journal:  Indian J Surg       Date:  2008-07-30       Impact factor: 0.656

4.  MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients.

Authors:  Sadra Samavarchi Tehrani; Ehsan Zaboli; Farzin Sadeghi; Soraya Khafri; Ansar Karimian; Mahnoosh Rafie; Hadi Parsian
Journal:  Biomedicine (Taipei)       Date:  2021-06-01

5.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

Authors:  Andrea Sassen; Justine Rochon; Peter Wild; Arndt Hartmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal:  Breast Cancer Res       Date:  2008-01-08       Impact factor: 6.466

6.  Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.

Authors:  Lobna Ayadi; Abdelmajid Khabir; Habib Amouri; Sondes Karray; Abdallah Dammak; Mohamed Guermazi; Tahya Boudawara
Journal:  World J Surg Oncol       Date:  2008-10-22       Impact factor: 2.754

7.  A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study.

Authors:  Huimin Zhang; Peiling Xie; Zhuoying Li; Rong Huang; Weiliang Feng; Yanan Kong; Feng Xu; Lin Zhao; Qingkun Song; Jing Li; Baoning Zhang; Jinhu Fan; Youlin Qiao; Xiaoming Xie; Shan Zheng; Jianjun He; Ke Wang
Journal:  Diagn Pathol       Date:  2019-05-04       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.